Immuno-polymeric drugs for prostate cancer therapy [ 2016 - 2018 ]

Research Grant

Researchers: A/Pr Kristofer Thurecht (Principal investigator) ,  E/Pr Andrew Boyd ,  Prof Pamela Russell ,  Prof Stephen Mahler

Brief description Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.

Funding Amount $AUD 644,857.58

Funding Scheme Project Grants

Notes Standard Project Grant